FDA warns about use of certain glucose monitoring strips

Share this article:

The Food and Drug Administration Friday issued a public health notification regarding certain glucose monitoring strips.

It said that healthcare practitioners should not use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinine ) test strips on patients receiving therapeutic products containing non-glucose sugars. These sugars can falsely elevate glucose results, which may mask hypoglycemia or prompt excessive insulin administration, leading to a serious injury or death, the FDA said. Patients with serious medical conditions, including kidney failure and rheumatoid arthritis are most likely to use these therapies. Diabetics use glucose monitoring strips to test their blood sugar levels.

Other glucose test strips do not react harmfully with the non-glucose sugars, the FDA noted. The unaffected methods are glucose oxidase, glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD) or glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD).

For more, click here.

 


Share this article:

More in News

Long-term care leaders need self-awareness, partnerships to avoid the 'Founder's Trap,' CEO panel advises

Long-term care leaders need self-awareness, partnerships to avoid ...

Strong leaders must be vigilant or they could stifle a company's innovation and growth, a CEO panel said Monday at the 2014 LINK LTC and Senior Living Conference in Chicago.

Coaching sessions reduce hospital readmissions, study finds

An hour-long educational coaching session and up to three follow-up phone calls reduced readmissions by 39% among Medicare patients, a new study finds.

County nursing home weighs heroin addict plan

An Ohio county is evaluating whether 20 beds at its nursing home could be dedicated for heroin addicts during their withdrawal, according to local reports.